AstraZeneca Caps Inhaler Costs at $35 Amid Political Pressure

The pharmaceutical giant's decision applies to uninsured or underinsured patients, aiming to make asthma and COPD treatments more affordable.

AstraZeneca announced it will cap out-of-pocket costs for its asthma and COPD inhalers at $35 a month, starting June 1.
The price cap follows similar moves by rival Boehringer Ingelheim and insulin manufacturers, amidst scrutiny from lawmakers and the FTC.
Sen. Bernie Sanders praised the move and urged other major inhaler manufacturers to adopt similar pricing caps.
The Asthma and Allergy Foundation of America welcomed the decision but emphasized the need for broader industry action to address drug affordability.
AstraZeneca's CEO Pascal Soriot highlighted the complexity of the healthcare system and called for reforms to ensure medication affordability.